Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injection
The launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch& Strategy, Vijay Raghavan said. The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2023 Category: Pharmaceuticals Source Type: news

Repurposed Drug Reverses Signs of Alzheimer's in Mice, Human Cells
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear. (Source: The Scientist)
Source: The Scientist - October 12, 2021 Category: Science Tags: News & Opinion Source Type: news

Bumetanide Promising for Reducing Autism Symptoms
TUESDAY, Feb. 4, 2020 -- Bumetanide seems effective for improving symptoms of autism spectrum disorder (ASD) in young children, according to a study published online Jan. 27 in Translational Psychiatry. Lingli Zhang, from the Shanghai Jiao Tong... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2020 Category: Pharmaceuticals Source Type: news

Diuretic a Promising Treatment for Autism Diuretic a Promising Treatment for Autism
The diuretic bumetanide improves some of the core symptoms of autism by decreasing levels of the neurotransmitters gamma-aminobutyric acid, new research shows.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - January 30, 2020 Category: Psychiatry Tags: Psychiatry News Source Type: news

Study Shows ‘ Water Pill ’ May Help Reduce Some Autism Symptoms In Young Kids
BOSTON (CBS) — A drug that has been used to treat heart failure for decades may improve behavioral symptoms in some young children with autism. Bumetanide is a diuretic, which is used to treat the buildup of fluid in the body. Researchers in China and at the University of Cambridge looked at 83 kids between three and six years old and found that, three months later, the children treated with the diuretic scored better on a behavior scale which measures emotional response as well as verbal and non-verbal communication. They believe the drug helps nerve cells communicate more effectively by reducing the level of a bra...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 27, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Seen On WBZ-TV Syndicated CBSN Boston Syndicated Local Autism Dr. Mallika Marshall Source Type: news

Could Common Diuretic Medicidne Bumetanide Help Ease Autism Symptoms?
MONDAY, Jan. 27, 2020 -- A prescription drug that ' s long been used to treat the buildup of fluid in the body might do double duty as a means of easing autism symptoms in young children, new research shows. If replicated in future trials, the drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 27, 2020 Category: General Medicine Source Type: news

Prescription drug improves symptoms of autism by targeting brain's chemical messengers
(University of Cambridge) Bumetanide -- a prescription drug for oedema (the build-up of fluid in the body) -- improves some of the symptoms in young children with autism spectrum disorders and has no significant side effects, according to a new study from researchers in China and the UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2020 Category: International Medicine & Public Health Source Type: news

Impaired regulation of KCC2 phosphorylation leads to neuronal network dysfunction and neurodevelopmental pathology
KCC2 is a vital neuronal K+/Cl– cotransporter that is implicated in the etiology of numerous neurological diseases. In normal cells, KCC2 undergoes developmental dephosphorylation at Thr906 and Thr1007. We engineered mice with heterozygous phosphomimetic mutations T906E and T1007E (KCC2E/+) to prevent the normal developmental dephosphorylation of these sites. Immature (postnatal day 15) but not juvenile (postnatal day 30) KCC2E/+ mice exhibited altered GABAergic inhibition, an increased glutamate/GABA synaptic ratio, and greater susceptibility to seizure. KCC2E/+ mice also had abnormal ultrasonic vocalizations at pos...
Source: Signal Transduction Knowledge Environment - October 14, 2019 Category: Science Authors: Pisella, L. I., Gaiarsa, J.-L., Diabira, D., Zhang, J., Khalilov, I., Duan, J., Kahle, K. T., Medina, I. Tags: STKE Research Articles Source Type: news

Lasix (furosemide) vs. bumetanide
Title: Lasix (furosemide) vs. bumetanideCategory: MedicationsCreated: 6/6/2019 12:00:00 AMLast Editorial Review: 6/6/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 6, 2019 Category: Cardiology Source Type: news

bumetanide, Bumex (discontinued brand)
Title: bumetanide, Bumex (discontinued brand)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 3/15/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 15, 2019 Category: Cardiology Source Type: news

Bumetanide Injection, USP (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 25, 2018 Category: Drugs & Pharmacology Source Type: news

Bumetanide Injection, USP (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - December 13, 2017 Category: Drugs & Pharmacology Source Type: news

Bumex (Bumetanide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 22, 2017 Category: Drugs & Pharmacology Source Type: news

Diuretic Continues to Show Promise in Autism Diuretic Continues to Show Promise in Autism
The diuretic bumetanide improved the core symptoms of autism spectrum disorder in a phase 2b study and will be tested in an upcoming phase 3 study in Europe.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 22, 2017 Category: Psychiatry Tags: Psychiatry News Source Type: news

Bumetanide Promising for Reducing Autism Symptoms
Decrease in GABA/glutamate ratio in insular cortex tied to symptom improvement in bumetanide group (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Family Medicine, Neurology, Pediatrics, Pharmacy, Psychiatry, Radiology, Journal, Source Type: news